Current Treatment Challenges of IO Refractory Patients and Clinical Development of Therapies Targeting These Patients
Over the years, the Oncology domain has experienced the entry of several treatment approaches. Therapeutic approaches such as surgery, radiation therapy, and chemotherapy form the conventional methods of combating cancers and are still the mainstays of cancer treatment; however, the recent emergence of immunotherapies, targeted therapies has also played an instrumental role in decreasing the cancer burden.
Immunotherapy has the potential to enable long-lasting immunity against cancer cells and increasing survival expectations. Extensive genomic studies have facilitated the identification of molecular biomarkers that directed the beginning of targeted therapies.
Immuno-oncology (I-O) therapeutics, despite yielding effective outcomes, remain associated with unpredictable outcomes with a risk of failure and adverse side-effects.
Through the white paper, DelveInsight aims to highlight the major therapy approaches with an exclusive focus on the current and future aspects of Immuno-oncology (I-O) therapeutics and the recent highlights and key developments in the field.